Vaccine
Is there a hantavirus vaccine?
Yes — in Asia. Inactivated hantavirus vaccines have been licensed in South Korea since 1990 and are administered widely in China. No hantavirus vaccine is licensed in the United States or European Union, and that's unlikely to change in the short term.
South Korea — Hantavax™
An inactivated whole-virus vaccine (originally suckling-mouse-brain–derived, now produced in cell culture) targeting Hantaan virus. First licensed in 1990; widely used in the South Korean military and other high-risk groups. Drawback: while immunofluorescence-assay seroconversion reaches ~90%, neutralizing-antibody seroconversion after the primary series is poor (~23% by PRNT50) and titers wane within 1–2 years; multiple booster doses are recommended.
China — bivalent inactivated vaccines
Several inactivated bivalent vaccines against Hantaan and Seoul are licensed and in nationwide use. Roughly 2 million doses are administered annually, and the programs are credited with the major drop in HFRS incidence in China since the 1990s.
United States & European Union
No licensed hantavirus vaccine. Reasons:
- Low case counts — ~30–50 reported HPS cases per year in the US.
- Geographically clustered population — primarily the western US.
- No commercial sponsor has pursued FDA / EMA approval.
- Cross-reactivity is limited: vaccines against Old World hantaviruses (Hantaan, Seoul) are not expected to protect against New World HPS viruses (Sin Nombre, Andes), so a US licensure would need a separate trial.
In development
- DNA vaccines — US Army Medical Research Institute of Infectious Diseases (USAMRIID) has run phase-1/2 trials of a Hantaan + Puumala DNA vaccine.
- Recombinant VSV-vectored Hantaan vaccines (single-dose, preclinical/early clinical).
- mRNA candidates — Korea University announced a partnership with Moderna in 2024 to develop an mRNA hantavirus vaccine.
What about post-exposure?
No post-exposure prophylaxis is approved. In severe cases of Old World HFRS, intravenous ribavirin reduces mortality if started in the first 4–7 days; ribavirin trials in HPS have not shown benefit. ECMO is the most effective intervention for HPS. See Syndromes — treatment.
Frequently asked questions
Is there a hantavirus vaccine in the US?
No. None is licensed by the FDA. Vaccines exist only in South Korea and China.
Why is there no US hantavirus vaccine?
Low annual case count, no commercial sponsor, and limited cross-protection between Old World vaccines and New World HPS viruses.
How effective is Hantavax?
Around 90% by older antibody assays, but neutralizing-antibody seroconversion is only ~23% after the primary series, and immunity wanes within 1–2 years.
Will the cruise-ship outbreak speed up vaccine development?
Possibly. The 2026 Andes-virus cluster has refocused attention on New World hantaviruses, and mRNA platforms can be reformulated quickly.